References
- Laughlin JS, Mohan R, Kutcher GJ. Choice of optimum megavoltage for accelerators for photon beam treatment. Int J Radiat Oncol1986; 12: 1551-7.
- NCRP. Report No. 79: Neutron contamination from medical electron accelerators.Bethesda, Maryland: NCRP; 1987.
- Westermark M, Arndt J, Nilsson B, Brahme A. Comparative dosimetry in narrow high-energy photon beams. Phys Med Biol 2000; 45: 685-702.
- Howell RM, Ferenci MS, Hertel NE, Fullerton GD. Investigation of secondary neutron dose for 18 MV dynamic MLC IMRT delivery. Med Phys 2005; 32: 786-93.
- Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol 2011; 34: 11-5.
- Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol 2008; 71: 1028-33.
- Soderstrom S, Eklof A, Brahme A. Aspects on the optimal photon beam energy for radiation therapy. Acta Oncol 1999; 38: 179-87.
- Park JM, Choi CH, Ha SW, Ye SJ. The dosimetric effect of mixed-energy IMRT plans for prostate cancer. J Appl Clin Med Phys 2011; 12: 3563.
- Sun M, Ma L. Treatments of exceptionally large prostate cancer patients with low-energy intensity-modulated photons. J Appl Clin Med Phys 2006; 7: 43-9.
- Sung W, Park JM, Choi CH, Ha SW, Ye SJ. The effect of photon energy on intensity-modulated radiation therapy (IMRT) plans for prostate cancer. Radiat Oncol J 2012; 30: 27-35.
- de Boer SF, Kumek Y, Jaggernauth W, Podgorsak MB. The effect of beam energy on the quality of IMRT plans for prostate conformal radiotherapy. Technol Cancer Res Treat 2007; 6: 139-46.
- Pasler M, Georg D, Wirtz H, Lutterbach J. Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer. Strahlenther Onkol 2011; 187: 792-8.
- Pirzkall A, Carol MP, Pickett B, Xia P, Roach M, 3rd, Verhey LJ. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol 2002; 53: 434-42.
- Welsh JS, Mackie TR, Limmer JP. High-energy photons in IMRT: uncertainties and risks for questionable gain. Technol Cancer Res Treat 2007; 6: 147-9.
- Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol 2008; 72: 996-1001.
- Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol2009; 93: 226-33.
- Shaffer R, Morris WJ, Moiseenko V, Welsh M, Crumley C, Nakano S, et al. Volumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study. Clin Oncol 2009; 21: 401-7.
- Zhang P, Happersett L, Hunt M, Jackson A, Zelefsky M, Mageras G. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol 2010; 76: 1456-62.
- Cozzi L, Dinshaw KA, Shrivastava SK, Mahantshetty U, Engineer R, Deshpande DD, et al. A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncology2008; 89: 180-91.
- Guckenberger M, Richter A, Krieger T, Wilbert J, Baier K, Flentje M. Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes? RadiotherOncol 2009; 93: 259-65.
- NCRP. Report No. 151: Structural shielding design and evaluation for mega-voltage x-and gamma-ray radiotherapy facilities.Bethesda, Maryland: NCRP; 2006.
- RTOG. RTOG 0534: A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (spport) in prostate cancer patients with a rising psa after radical prostatectomy.Philadelphia, Pennsylvania: RTOG; 2013.
- ICRU. Report No. 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, Maryland: ICRU; 1999.
- R Core Team. R:A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
- Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol 2000; 47: 103-13.
- Rossi JS. Statistical power of psychological research: What have we gained in 20 years? J Consult Clin Psych1990; 58: 646-56.
- Cohen J. Approximate power and sample size determination for common one-sample and two-sample hypothesis tests. Educ Psychol Meas1970; 30: 811-31.
- de Winter JC. Using the Student's t-test with extremely small sample sizes. Practical Assessment, Research & Evaluation2013; 18: 1-12.
- Ost P, Speleers B, De Meerleer G, De Neve W, Fonteyne V, Villeirs G, et al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol 2011; 79: 920-6.
- Mattes MD, Tai C, Lee A, Ashamalla H, Ikoro NC. The dosimetric effects of photon energy on the quality of prostate volumetric modulated arc therapy. Pract Radiat Oncol 2014; 4: e39-44.
- Chow JC, Grigorov GN, Barnett RB. Study on surface dose generated in prostate intensity-modulated radiation therapy treatment. Med Dosim 2007; 31: 249-58.
- Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol 2007; 68: 1265-71.